By John Kamp, Executive Director, Coalition for Healthcare Communication June 29, 2011 — Yesterday I had the pleasure of moderating a lively panel discussion at the 2011 BIO annual meeting in D.C., titled: “Talking About Your Product in the New Age: Social Media and the Internet.” While every speaker recognized the regulatory uncertainty and complexity […]
Read moreTag: social media
social mediaAd Coalition: Online DTC Studies Should Not Further Delay FDA Social Media Guidance
June 27, 2011 — The Food and Drug Administration (FDA) should move forward with its social media/Internet guidance and not wait for the results of the three studies it recently announced it would conduct to test benefit and risk information presentations on direct-to-consumer (DTC) prescription drug Web sites, according to comments submitted to the FDA […]
Read moreLegal Guide Spells Out Social Media’s Risks, Benefits
June 9, 2011 — A new White Paper by the law firm Reed Smith demonstrates that the perils of social media go well beyond waiting for guidance from the FDA. The guide, free to employees of 4As agencies and other supporters of the Coalition for Healthcare Communication, can be downloaded using the link below. “Okay, so […]
Read moreDo Not Track: Coming Soon to a Mobile Device Near You?
May 27, 2011 — As Congress considers six pieces of pending legislation introduced to protect consumers’ privacy online – all but one of which recommends mandatory “Do Not Track” provisions – the Senate Committee on Commerce, Science & Transportation last week held a hearing to discuss whether Do Today saw a good website Not Track […]
Read moreMore Social Media Studies Planned at FDA
Immediate Guidance Slips Again May 9, 2011 – A recent notice in the Federal Register calling for comments on a series of Food and Drug Administration (FDA) studies to determine the most effective way of presenting risk information online indicates that the FDA is still a long way from developing significant new social media guidance. This status […]
Read moreInnovate with Social Media While Waiting for FDA Guidance, Says Coalition Executive Director
April 11, 2011 – While waiting for the Food and Drug Administration’s (FDA’s) Division of Drug Marketing, Advertising, and Communications (DDMAC) to begin issuing social media guidance, it is important for agencies and clients to create compelling sites for professionals and patients that stay within the FDA’s existing policies, according to John Kamp, executive director […]
Read morePew Survey Confirms Importance of Internet to Consumers
March 4, 2011 — Although the medicines industry is treading carefully in its use of Internet marketing, new research confirms that consumer use of the Internet is growing. Consumers both use and value the ability to research health topics online, according to the recently released results of a Pew Internet Project/California HealthCare Foundation survey. Meanwhile, pharmaceutical companies […]
Read moreRough Seas or Smooth Sailing? Navigating Pharma’s Role in Social Media Marketing
Feb. 14, 2011 — As more and more pharmaceutical companies explore the addition or expansion of social media marketing efforts, they are seeking to balance the perceived benefits of such marketing with the slow emergence of metrics to validate those benefits. However, it appears that social media marketing is gaining traction, according to a recent Harvard […]
Read more
General
Coalition Focus for 2011
Coalition Focus for 2011
Although 2011 brings political party shifts in Congress and new challenges, the mission of the Coalition for Healthcare Communication (CHC) remains the same: To protect, for society and individual patients, the benefit of the free flow of healthcare information. This year the CHC will be focusing on four major issues: (1) tax treatment of marketing […]
Read more
General
Add Your New Year Predictions to Our Industry Leaders'
Add Your New Year Predictions to Our Industry Leaders'
2011 Medical Marketing Predictions published in Medical Marketing & Media, December 30, 2010 — by Matthew Arnold Will 2011 be the year FDA loosens up and opens the floodgates on a flurry of big new approvals? More seriously, will they get around to issuing social media guidance for pharma before Baby New Year morphs into […]
Read more